ReWalk Robotics (NASDAQ:LFWD) Releases Quarterly Earnings Results, Misses Expectations By $1.53 EPS

ReWalk Robotics (NASDAQ:LFWD) released its quarterly earnings data on Friday. The company reported ($1.73) EPS for the quarter, missing the consensus estimate of ($0.20) by ($1.53), Zacks reports. ReWalk Robotics had a negative net margin of 77.21% and a negative return on equity of 43.02%. The business had revenue of $7.55 million for the quarter, compared to analysts’ expectations of $7.30 million. ReWalk Robotics updated its FY 2025 guidance to EPS.

ReWalk Robotics Trading Up 3.2 %

Shares of LFWD opened at $1.63 on Friday. The business’s 50 day moving average is $1.76 and its 200 day moving average is $2.26. The company has a market capitalization of $17.33 million, a PE ratio of -0.65 and a beta of 1.73. ReWalk Robotics has a 12-month low of $1.25 and a 12-month high of $6.00.

Analysts Set New Price Targets

Several brokerages have issued reports on LFWD. Lake Street Capital dropped their target price on ReWalk Robotics from $6.00 to $4.50 and set a “buy” rating on the stock in a research report on Thursday, February 20th. Laidlaw assumed coverage on ReWalk Robotics in a research report on Monday, February 10th. They set a “buy” rating and a $10.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $13.00 price objective on shares of ReWalk Robotics in a research report on Thursday, February 20th.

Insider Activity at ReWalk Robotics

In other news, major shareholder Global Fund Lp Lind II sold 381,676 shares of ReWalk Robotics stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $3.36, for a total value of $1,282,431.36. Following the completion of the transaction, the insider now owns 1,049,430 shares in the company, valued at approximately $3,526,084.80. The trade was a 26.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.50% of the stock is owned by corporate insiders.

About ReWalk Robotics

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.